Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice

被引:49
|
作者
Sun, Lei [1 ]
Yang, Xiaoxiao [2 ]
Li, Qi [1 ]
Zeng, Peng [1 ]
Liu, Ying [1 ]
Liu, Lipei [1 ]
Chen, Yuanli [2 ]
Yu, Miao [1 ]
Ma, Chuanrui [1 ]
Li, Xiaoju [1 ]
Li, Yan [1 ]
Zhang, Rongxin [3 ]
Zhu, Yan [4 ]
Miao, Qing Robert [5 ,6 ]
Han, Jihong [2 ,7 ]
Duan, Yajun [2 ,7 ]
机构
[1] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, Tianjin, Peoples R China
[2] Hefei Univ Technol, Coll Biomed Engn, Dept Biomed Sci, Hefei, Peoples R China
[3] Tianjin Med Univ, Dept Physiol, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Pharmacol, Tianjin, Peoples R China
[5] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA
[6] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[7] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China
基金
中国国家自然科学基金; 对外科技合作项目(国际科技项目);
关键词
adiponectin; adiponectin receptors; AMP-activated protein kinases; atherosclerosis; peroxisome proliferator-activated receptors; PLASMA-PROTEIN; PPAR-GAMMA; PCSK9; CHOLESTEROL; TRANSCRIPTION; MODULATOR; LIGANDS; AGONIST; STATINS; BINDING;
D O I
10.1161/ATVBAHA.117.309630
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPAR gamma (peroxisome proliferator-activated receptor.) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. Approach and Results-At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPAR gamma expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPAR gamma deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase alpha (AMPK alpha) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPAR gamma, AMPK alpha and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE(-/-)) mice, but it still activated hepatic LDLR, PPAR gamma, AMPK alpha, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE(-/-) mice with amelioration of lipid profiles. Conclusions-Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wildtype and apoE(-/-) mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE(-/-) mice. Visual Overview-An online visual overview is available for this article.
引用
收藏
页码:1290 / +
页数:22
相关论文
共 50 条
  • [41] Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
    Gu, Hong-mei
    Zhang, Da-wei
    JOURNAL OF BIOMEDICAL RESEARCH, 2015, 29 (05): : 356 - 361
  • [42] Expression and regulation of proprotein convertase subtilisin/kexin type 9 in vascular smooth muscle cells
    Stawowy, P.
    Meyborg, H.
    Bezhaeva, T.
    Fritzsche, J.
    Molnar, S.
    Urban, D.
    Fleck, E.
    EUROPEAN HEART JOURNAL, 2013, 34 : 763 - 763
  • [43] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 DEFICIENT MICE ARE PROTECTED FROM NEOINTIMA FORMATION IN CAROTID ARTERY INJURY MODEL
    Ferri, N.
    Tibolla, G.
    Baetta, R.
    Corsini, A.
    Catapano, A.
    ATHEROSCLEROSIS, 2014, 235 (02) : E21 - E22
  • [44] Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
    Garcon, Damien
    Moreau, Francois
    Ayer, Audrey
    Dijk, Wieneke
    Prieur, Xavier
    Arnaud, Lucie
    Roubtsova, Anna
    Seidah, Nabil
    Prat, Annik
    Cariou, Bertrand
    Le May, Cedric
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (09) : 2084 - 2094
  • [45] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [46] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [47] The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in HyperlipidemiaFocus on Therapeutic Implications
    Michel Farnier
    American Journal of Cardiovascular Drugs, 2011, 11 : 145 - 152
  • [48] The role of proprotein convertase subtilisin/kexin type 9 inhibitors in clinical practice
    Blanquez Martinez, David
    Hayon Ponce, Maria
    Caballero Romero, Alvaro
    Nieto Gomez, Pelayo
    Diaz Villamarin, Xando
    Alvarez Sanchez, Raquel
    Cabeza Barrera, Jose
    Davila Fajardo, Cristina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 302 - 302
  • [49] Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (03) : 269 - 275
  • [50] Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9
    Lagace, Thomas A.
    Bashmakov, Yuriy
    Anderson, Norma N.
    McNutt, Markey C.
    Grefhorst, Aldo
    Ho, Y. K.
    Horton, Jay D.
    FASEB JOURNAL, 2008, 22